Get the Stockscreener App
1.75
4.79%
0.08
After Hours:
1.75
Codexis Inc stock is traded at $1.75, with a volume of 1.15M.
It is up +4.79% in the last 24 hours and up +56.25% over the past month.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$1.67
Open:
$1.69
24h Volume:
1.15M
Relative Volume:
0.56
Market Cap:
$159.02M
Revenue:
$70.39M
Net Income/Loss:
$-43.97M
P/E Ratio:
-3.3777
EPS:
-0.5181
Net Cash Flow:
$-23.85M
1W Performance:
+19.05%
1M Performance:
+56.25%
6M Performance:
-27.08%
1Y Performance:
-40.48%
1-Day Range:
$1.69
$1.7893
1-Week Range:
$1.42
$1.7893
52-Week Range:
$0.9583
$3.87
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.75 | 151.75M | 70.39M | -43.97M | -23.85M | -0.5181 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Analyst sentiment unchanged after Codexis (CDXS) earnings - MSN
Analyst Sentiment Unchanged After Codexis (CDXS) Earnings - Insider Monkey
Codexis rises after Q4 beat, strong outlook - MSN
Benchmark reiterates Hold on Codexis stock after Q4 results By Investing.com - Investing.com India
Benchmark reiterates Hold on Codexis stock after Q4 results - Investing.com
Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS) - marketscreener.com
Why did Codexis (CDXS) stock soar nearly 38% after hours? - MSN
Biocatalysis Market Accelerates with Rising Demand - openPR.com
Jobs Data: Does Codexis Inc offer margin of safety2026 Weekly Recap & Risk Controlled Swing Alerts - baoquankhu1.vn
CDXS Stock Price, Quote & Chart | CODEXIS INC (NASDAQ:CDXS) - ChartMill
Fund Flows: Is Codexis Inc stock technically oversold2026 Chart Watch & Weekly High Return Stock Opportunities - baoquankhu1.vn
Biocatalysis and Biocatalysts Market is expected to Hit US$ 6.7 - openPR.com
Codexis (CDXS) beats Q4 earnings and revenue estimates - MSN
Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue GuidanceHas The Bull Case Changed? - simplywall.st
Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2% - MarketBeat
Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance - Yahoo Finance
Codexis Faces Strategic Challenges Amidst Revenue Dip - timothysykes.com
Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement - simplywall.st
Codexis (NASDAQ:CDXS) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Codexis Stock Plummets Amid Financial Struggles - StocksToTrade
Why did CDXS stock jump 7% today? - MSN
Cantor Fitzgerald Maintains Overweight on Codexis (CDXS) March 2026 - Meyka
Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative - Sahm
Dow Tumbles Over 1%; US Weekly Jobless Claims Fall - Sahm
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours? - Sahm
Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results - Sahm
Codexis (CDXS) Stock Jumps 2.4% Following Strong Q4 Earnings Report - MEXC
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance - Investing.com UK
Cantor Fitzgerald reiterates Codexis stock rating on siRNA deal By Investing.com - Investing.com South Africa
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS) - Seeking Alpha
Codexis (CDXS) Stock Rises 2.4% After Q4 Earnings Beat - MEXC
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance By Investing.com - Investing.com India
Codexis Shines as Q4 Profit Sparks Investor Enthusiasm - StocksToTrade
Cantor Fitzgerald reiterates Codexis stock rating on siRNA deal - Investing.com
Codexis Surpasses Q4 Expectations, Stock Price Volatility Anticipated - timothysykes.com
Codexis (CDXS) Q4 2025 Earnings Call Transcript - AOL.com
Codexis stock jumps on Q4 earnings beat, strong 2026 outlook - National Today
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):